NEWS DETAIL

Alkem Launches Perampil (Perampanel Tablets) at Affordable Prices and Improved Patient Access for Epilepsy Treatment in India

Mumbai, India, June 10, 2021: Alkem Laboratories Ltd. (Alkem), one of the India's leading pharmaceutical formulation development, manufacturing, and marketing companies, announces the launch of Perampil (Perampanel) tablets 2 mg/4 mg/6 mg on June 9th 2021 to make the treatment accessible to patients and healthcare providers improving their quality of life. Alkem has launched Perampil, at 2 mg – Rs. 49/strip of 7 tablets, 4 mg – Rs. 180/strip of 15 tablets and 6 mg – Rs. 300/strip of 15 tablets, to improve patient access.

This product reaffirms Alkem’s commitment towards improving epilepsy care by bringing multiple treatment options of quality products to patients and health care professionals in India. Alkem had also launched Brivasure (Brivaracetam) tablets in March 2021 for the adjunctive management of partial onset seizure with or without secondary generalization. 

The drug, Perampanel, has been approved by the Drugs Controller General of India (DCGI), as an adjunctive therapy in treatment of partial onset seizures in patients with epilepsy aged 4 years and older and also as an adjunctive therapy in treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older. Alkem continues to work persistently towards the production of top-quality products to improve patient access and quality of life for them. 

References: 

 

  1. Potschka H, Trinka E. Perampanel: Does it have broad%u2010spectrum potential?. Epilepsia. 2019 Mar; 60:22-36 
  2. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202834s016,208277s004lbl.pdf accessed on 9/6/21
About Alkem Laboratories Ltd. 

Established in 1973 and headquartered in Mumbai, Alkem (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and International markets. With a portfolio of more than 800 brands in India, Alkem is ranked the fifth largest pharmaceutical company in India in terms of domestic sales (Source: IQVIA data March 2021). The Company also has presence in more than 40 international markets, with the United States being its key focus market. 

For more information on Alkem Laboratories Ltd., please visit www.alkemlabs.com.